相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection
Katarina Tomovic et al.
MEDICINAL RESEARCH REVIEWS (2019)
Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
Yohei Kawaguchi et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Clifford J. Bailey et al.
DIABETES OBESITY & METABOLISM (2019)
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
FRONTIERS IN ENDOCRINOLOGY (2019)
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
Giorgio Sesti et al.
ACTA DIABETOLOGICA (2019)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019
William T. Cefalu et al.
DIABETES CARE (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Alaa G. Almagthali et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2019)
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin - (CARMELINA (R)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Julio Rosenstock et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin
Stefano Del Prato et al.
DIABETES OBESITY & METABOLISM (2018)
Incretin hormones: Their role in health and disease
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2018)
The safety of gliptins : updated data in 2018
Andre Jacques Scheen
EXPERT OPINION ON DRUG SAFETY (2018)
Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
Lana C. Pinto et al.
SCIENTIFIC REPORTS (2018)
The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus A systemic review and meta-analysis
Xianying Wang et al.
MEDICINE (2018)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2018)
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETOLOGIA (2018)
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes
Ivan Tkac et al.
DIABETES CARE (2017)
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon- like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2017)
Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial
Ronald M. Goldenberg
CLINICAL THERAPEUTICS (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes
Cristina Bianchi et al.
DRUGS (2017)
Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials
A. S. Abbas et al.
DIABETES OBESITY & METABOLISM (2016)
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes A Meta-analysis
Suetonia C. Palmer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus Secondary Analysis of a Randomized Clinical Trial
Darren K. McGuire et al.
JAMA CARDIOLOGY (2016)
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Sung-Ho Kim et al.
DIABETES & METABOLISM JOURNAL (2016)
Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
Xiao-Wu Chen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
Safety of antidiabetes medications: An update
C. J. Bailey
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Nikolaus Marx et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
Stephan Matthaei et al.
DIABETES CARE (2015)
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
Chantal Mathieu et al.
DIABETES CARE (2015)
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
Andrew Lewin et al.
DIABETES CARE (2015)
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
Ralph A. DeFronzo et al.
DIABETES CARE (2015)
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETOLOGIA (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
Baptist Gallwitz
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2015)
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
Julio Rosenstock et al.
DIABETES CARE (2015)
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
Jacob A. Udell et al.
DIABETES CARE (2015)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and Isoglycemic Intravenous Glucose
Irfan Vardarli et al.
DIABETES (2014)
Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
Changting Xiao et al.
DIABETES (2014)
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2014)
Risk of pancreatitis in patients treated with incretin-based therapies
Juris J. Meier et al.
DIABETOLOGIA (2014)
Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors
Bhumika D. Patel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Thomas Karagiannis et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Jennifer B. Green et al.
AMERICAN HEART JOURNAL (2013)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler et al.
DIABETES (2013)
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Michael A. Nauck
DIABETES CARE (2013)
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial
O. Mosenzon et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2013)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
Carolyn F. Deacon et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial
Burkhard Goeke et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
William B. White et al.
AMERICAN HEART JOURNAL (2011)
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
R. Arechavaleta et al.
DIABETES OBESITY & METABOLISM (2011)
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy
Baptist Gallwitz
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
D. R. Matthews et al.
DIABETES OBESITY & METABOLISM (2010)
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
C. Filozof et al.
DIABETIC MEDICINE (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
S. S. Engel et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs
M. Odette Gore et al.
Current Cardiology Reports (2009)
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
V. Fonseca et al.
HORMONE AND METABOLIC RESEARCH (2008)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Contributions of insulin-resistance and insulin-secretory defects to the pathognesis of type 2 diabetes mellitus
JE Gerich
MAYO CLINIC PROCEEDINGS (2003)
分享论文
